AstraZeneca licenses inflammatory disease candidate to Allergan

LONDON (Reuters) - Britain's AstraZeneca said it had licensed a potential medicine for inflammatory diseases to Allergan for an upfront payment of $250 million and potential additional payments of up to $1.27 billion.